Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RP-3500 (camonsertib) in advanced solid tumors with ATR inhibitor sensitizing mutations
NCT04497116Phase 2Completed
- Sponsor
- Repare Therapeutics
- Start
- Jul 2020
- Primary completion
- Jun 2025
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 2, open-label trial of camonsertib in solid tumor (advanced stage) (3 arms), sponsored by Repare Therapeutics. Primary endpoints: Frequency of Treatment-Related Adverse Event of CTCAE Grade 3 and Above up to 1 year and Dose Limiting Toxicity at 28 days. Started Jul 2020; status: completed.
02
Drugs
camonsertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04497116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04497116.